Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals

Core Insights - Enthorin Therapeutics, LLC is focused on circuit-modulating treatments for neurological and neurodevelopmental disorders [1] - The company announced that its licensing partner, Mirum Pharmaceuticals, initiated the BLOOM Phase 2 clinical study for MRM-3379 in Fragile X syndrome [1] - MRM-3379 is characterized as an orally available, highly brain-penetrant, selective phosphodiesterase inhibitor [1] Company Overview - Enthorin Therapeutics specializes in biotechnology with a focus on neurological and neurodevelopmental disorders [1] - Mirum Pharmaceuticals, Inc. is the licensing partner for MRM-3379 and is publicly traded on NASDAQ under the ticker MIRM [1] Clinical Development - The BLOOM Phase 2 clinical study aims to evaluate the efficacy of MRM-3379 in treating Fragile X syndrome [1] - MRM-3379 is noted for its ability to penetrate the brain effectively, which is crucial for its therapeutic application [1]